BPA/NEG026250UC cordycepin 5'-triphosphate 3'-[alpha-32-P. This is a radioactive order.
Ended Awarded Last action
- Contract number
- HHSN26100030
- Awardee
-
Revvity Health Sciences, Inc. UEI G2TETZJTELL4 Part of Revvity Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $12,390
Award facts
- Contract value 100% obligated
- $12,390.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Shelton, CT 06484, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,390 | |
| Original award | $13,780 |
About this award
On October 18, 2012, the National Cancer Institute awarded a Blanket Purchase Agreement (BPA) call valued at $12,390 to Revvity Health Sciences, Inc. (doing business as PerkinElmer Inc.) for the procurement of Cordycepin 5'-triphosphate 3'-[alpha-32-P], a radioactive order. The contract was completed on October 22, 2013, and utilized firm fixed-price pricing with no small business set-aside designation. The work was performed in Shelton, Connecticut. Revvity Health Sciences is a subsidiary of Revvity Inc. and specializes in providing advanced scientific equipment, laboratory instruments, and specialized research technologies to federal agencies across multiple domains.
This procurement falls under a larger Indefinite Delivery Vehicle structure, demonstrating Revvity's established role as a critical supplier of specialized scientific materials and equipment to the National Institutes of Health and its constituent institutes. The radioactive compound procured under this order supports the National Cancer Institute's research and diagnostic capabilities. Revvity's federal contract portfolio reflects its extensive experience supplying scientific instrumentation, reagents, maintenance services, and specialized research materials to civilian and defense agencies, positioning it as a capable provider of the specialized radioactive materials required for advanced cancer research initiatives.
Quick answers
Who was awarded contract HHSN26100030?
HHSN26100030 was awarded to Revvity Health Sciences, Inc. by National Cancer Institute (National Institutes of Health) on October 18, 2012.
How much is contract HHSN26100030 worth?
The government has obligated $12,390 on HHSN26100030.
Is contract HHSN26100030 an order under another contract?
Yes. HHSN26100030 is a BPA call under HHSN263199800049720B, a blanket purchase agreement.
Was contract HHSN26100030 competed?
The extent of competition for HHSN26100030 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award